Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123

US10906978B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Jana Albrecht · Frankfurt, DE
• Cédric Barriere · Paris, FR
• Christian Beil · Frankfurt am Main, DE
• Jochen BENINGA · Frankfurt am Main, DE
• Chantal Carrez · Saint-Avertin, FR
• Stéphane Guerif · Paris, FR
• Katja Kroll · Frankfurt, DE
• Christian Lange · Frankfurt am Main, DE
• Cendrine Lemoine · Paris, FR
• Wulf-Dirk Leuschner · Frankfurt am Main, DE
• Ercole Rao · Frankfurt am Main, DE
• Marion SCHNEIDER · Hofheim, DE
• Marie-Cécile Wetzel · Paris, FR
• Peter Wonerow · Wildau, DE

Key dates

• Filing date: Apr 2, 2018
• Grant date: Feb 2, 2021
• Expiry date: Apr 2, 2038

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/7155
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.